PRM-151 has shown broad anti-
fibrotic and anti-inflammatory activity in multiple preclinical models of
fibrotic disease and inflammation, including pulmonary fibrosis, acute and chronic nephropathy, glaucoma, age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
HT-100 works by inhibiting the pathological
fibrotic process in muscle and directly stimulating healthy muscle fiber regeneration.
Emricasan has the potential to be a promising treatment for patients with
fibrotic diseases of various etiologies, an area of high unmet medical need, and I am enthusiastic and excited about the company's potential to realize these possibilities.
We are excited to advance PRM-151 into this clinical study in patients with IPF, as we believe that PRM-151 represents a novel and powerful first-in-class agent to prevent and treat a wide variety of serious
fibrotic diseases, including IPF," said Dominick Colangelo, President and Chief Executive Officer of Promedior.
These findings highlight the potential of Pentraxin-2 to be a potent and durable inhibitor at a pivotal point in the disease pathway of progressive pulmonary
fibrotic diseases.
Research completed in the laboratory of Michael Brenner, MD, at Brigham and Women's Hospital and Harvard Medical School, and at Adheron Therapeutics has implicated Cad-11 in the disease processes leading to rheumatoid arthritis and a number of
fibrotic diseases.
We hypothesized that for those ears showing a
fibrotic tissue link to the ossicles, the CC threshold will be lower than that for BC at frequencies below 2.
The study discovered that a molecule on these cells is a key regulator of
fibrotic disease.
Such high numbers of crosslinks are characteristic of "changes we see in humans with
fibrotic lung disease,' Last says.
Its unique qualities may enable it to intervene in the pathophysiology of diabetic nephropathy as well as other forms of kidney disease and certain
fibrotic indications.
These collective preclinical results provide a strong rationale to explore treatment with MMI-0100 in a variety of pulmonary disorders, including both obstructive and
fibrotic lung diseases.
TD139 is a extremely potent, hyperlocalized inhibitor that aims
fibrotic tissue in the lungs and reduces systemic exposure.
